Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « Bruno Fautrel »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Bruno Dallapiccola < Bruno Fautrel < Bruno H. Muller  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]
Ident.Authors (with country if any)Title
000050 (2019-06-12) Kedra Joanna [France] ; Philippe Dieudé [France] ; Hubert Marotte [États-Unis] ; Alexandre Lafourcade [France] ; Emilie Ducourau [France] ; Thierry Schaeverbeke [France] ; Aleth Perdriger [France] ; Martin Soubrier [France] ; Jacques Morel [France] ; Arnaud Constantin [Royaume-Uni] ; Emmanuelle Dernis [France] ; Valérie Royant [France] ; Jean-Hugues Salmon [France] ; Thao Pham [France] ; Jacques-Eric Gottenberg [France] ; Edouard Pertuiset [France] ; Maxime Dougados [France] ; Valérie Devauchelle-Pensec [France] ; Philippe Gaudin [France] ; Gregoire Cormier [France] ; Philippe Goupille [France] ; Xavier Mariette [France] ; Francis Berenbaum [France] ; Didier Alcaix [France] ; Sid Ahmed Rouidi [France] ; Jean-Marie Berthelot [France] ; Agnès Monnier [France] ; Christine Piroth [France] ; Frederic Liote [France] ; Vincent Goeb [France] ; Cécile Gaujoux-Viala [France] ; Isabelle Chary Valckenaere [France] ; David Hajage [France] ; Florence Tubach [France] ; Bruno Fautrel [France]Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission
000107 (2019) Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raimon Sanmarti [Espagne] ; Min Bao [États-Unis] ; Jenny Devenport [États-Unis] ; Attila Pethö-Schramm [Suisse]Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
000123 (2019) Sebastiaan J. Vastert [Pays-Bas] ; Yvan Jamilloux [France] ; Pierre Quartier [France] ; Sven Ohlman [Suède] ; Lisa Osterling Koskinen [Suède] ; Torbjörn Kullenberg [Suède] ; Karin Franck-Larsson [Suède] ; Bruno Fautrel [France] ; Fabrizio De Benedetti [Italie]Anakinra in children and adults with Still’s disease
000124 (2019) François Vercruysse [France] ; Thomas Barnetche [France] ; Estibaliz Lazaro [France] ; Emilie Shipley [France] ; François Lifermann [France] ; Alexandre Balageas [France] ; Xavier Delbrel [France] ; Bruno Fautrel [France] ; Christophe Richez [France] ; Thierry Schaeverbeke [France] ; Marie-Elise Truchetet [France]Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy
000157 (2018) Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse]Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
000163 (2018) Pauline Richebé [France] ; Florian Bailly [France] ; Louise Laure Mariani [France] ; Paola Sanchez Pena [France] ; Jean Michel Pedespan [France] ; Bruno Fautrel [France]Report of two cases of tocilizumab induced recurrent meningitis or meningoencephalitis.
000173 (2018) Cem Gabay [Suisse] ; Bruno Fautrel [France] ; Jürgen Rech [Allemagne] ; François Spertini [Suisse] ; Eugen Feist [Allemagne] ; Ina Kötter [Allemagne] ; Eric Hachulla [France] ; Jacques Morel [France] ; Thierry Schaeverbeke [France] ; Mohamed A. Hamidou [France] ; Thierry Martin [France] ; Bernhard Hellmich [Allemagne] ; Peter Lamprecht [Allemagne] ; Hendrik Schulze-Koops [Allemagne] ; Delphine Sophie Courvoisier [Suisse] ; Andrew Sleight [Suisse] ; Eduardo Jorge Schiffrin [Suisse]Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
000176 (2018) Eugen Feist [Allemagne] ; Stéphane Mitrovic [France] ; Bruno Fautrel [France]Mechanisms, biomarkers and targets for adult-onset Still’s disease
000205 (2018) Bruno Fautrel [France] ; Rieke Alten [Allemagne] ; Bruce Kirkham ; Inmaculada De La Torre [États-Unis] ; Frederick Durand [France] ; Jane Barry ; Thorsten Holzkaemper [Allemagne] ; Walid Fakhouri [États-Unis] ; Peter C. Taylor [Royaume-Uni]Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
000223 (2017) Lise M. Verhoef [Pays-Bas] ; Lieke Tweehuysen [Pays-Bas] ; Marlies E. Hulscher [Pays-Bas] ; Bruno Fautrel [France] ; Alfons A. Den Broeder [Pays-Bas]bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
000239 (2017) Johanna Sigaux [France] ; Florian Bailly [France] ; David Hajage [France] ; Xavier Mariette [France] ; Jacques Morel [France] ; Frédérique Gandjbakhch [France] ; Violaine Foltz [France] ; Laure Gossec [France] ; Florence Tubach [France] ; Bruno Fautrel [France]Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
000240 (2017) Ernest Choy [Royaume-Uni] ; Roberto Caporali [Italie] ; Ricardo Xavier [Brésil] ; Bruno Fautrel [France] ; Raim N Sanmarti [Espagne] ; Min Bao [États-Unis] ; Corrado Bernasconi [Suisse] ; Attila Pethö-Schramm [Suisse]Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
000280 (2017) Christopher J. Edwards [Royaume-Uni] ; Bruno Fautrel [France] ; Hendrik Schulze-Koops [Allemagne] ; Tom W J. Huizinga [Pays-Bas] ; Klaus Kruger [Allemagne]Dosing down with biologic therapies: a systematic review and clinicians’ perspective
000364 (2016) Anais Gardette [France] ; Sébastien Ottaviani [France] ; Jérémie Sellam [France] ; Francis Berenbaum [France] ; Frédéric Lioté [France] ; Bruno Fautrel [France] ; Elisabeth Palazzo [France] ; Alain Meyer [France] ; Jean Sibilia [France] ; Philippe Dieudé [France]Body mass index and response to abatacept in rheumatoid arthritis
000479 (2014) Bruno Fautrel [France]Intérêt de la monothérapie par le tocilizumab dans la polyarthrite rhumatoïde: un autre comparateur s'impose
000623 (2012) Cecilia Giampietro [Italie] ; Bruno Fautrel [France]Anti-Interleukin-1 Agents in Adult Onset Still's Disease
000624 (2012) Petros Efthimiou [États-Unis] ; L. Nandini Moorthy [États-Unis] ; Clio P. Mavragani [Grèce] ; Dimitris Skokos [États-Unis] ; Bruno Fautrel [France]Adult Onset Still's Disease and Autoinflammation
000683 (2011) Bruno Fautrel [France]Stratégies thérapeutiques
000699 (2011) Robert Launois [France] ; Bernard Avouac ; Francis Berenbaum ; Olivier Blin ; Isabelle Bru ; Bruno Fautrel ; Jean-Michel Joubert ; Jean Sibilia ; Bernard CombeComparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis
000700 (2010-06) Thao Pham ; Pascal Claudepierre [France] ; Arnaud Constantin ; Michel De Bandt ; Bruno Fautrel [France] ; Laure Gossec [France] ; Jacques-Eric Gottenberg ; Philippe Goupille [France] ; Severine Guillaume [France] ; Eric Hachulla [France] ; Charles Masson ; Jacques Morel [France] ; Xavier Puechal ; Alain Saraux ; Thierry Schaeverbeke [France] ; Daniel Wendling ; Eric Bruckert [France] ; Stanislas Pol [France] ; Xavier Mariette [France] ; Jean SibiliaTocilizumab therapy and safety management
000703 (2010) Thao Pham [France] ; Pascal Claudepierre ; Arnaud Constantin ; Michel De Bandt ; Bruno Fautrel ; Laure Gossec ; Jacques-Eric Gottenberg ; Philippe Goupille ; Séverine Guillaume ; Eric Hachulla ; Charles Masson ; Jacques Morel ; Xavier Puéchal ; Alain Saraux ; Thierry Schaeverbeke ; Daniel Wendling ; Eric Bruckert ; Stanislas Pol ; Xavier Mariette ; Jean SibiliaTocilizumab: therapy and safety management.

List of associated KwdEn.i

Nombre de
documents
Descripteur
7Humans
6Chronic
6Rheumatoid arthritis
5Arthritis, Rheumatoid (drug therapy)
5Female
4Adult
4Antirheumatic Agents (therapeutic use)
4Male
4Middle Aged
4Rheumatology
4Treatment
3Antibodies, Monoclonal (therapeutic use)
3Antibodies, Monoclonal, Humanized
3Antibodies, Monoclonal, Humanized (therapeutic use)
3Biotherapy
3Treatment Outcome
2Aged
2Antibodies, Monoclonal (adverse effects)
2Antibodies, Monoclonal, Humanized (administration & dosage)
2Antirheumatic Agents (administration & dosage)
2Drug Therapy, Combination
2Glucocorticoids (therapeutic use)
2Immunomodulator
2Injections, Subcutaneous
2Interleukin 1 Receptor Antagonist Protein (therapeutic use)
2Still's Disease, Adult-Onset (diagnosis)
2Still's Disease, Adult-Onset (drug therapy)
2Tocilizumab
1Adolescent
1Adult-onset Still's disease
1Anakinra
1Anti-Tumor Necrosis Factor-alpha
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antirheumatic agent
1Arthritis, Rheumatoid (diagnosis)
1Bayes Theorem
1Biological treatment
1Biologics Key messages
1Cartilage, Articular (drug effects)
1Cartilage, Articular (pathology)
1Certolizumab Pegol
1Certolizumab pegol
1Chronic Disease
1Comparative study
1Contraindications
1Diffusion Magnetic Resonance Imaging (methods)
1Double-Blind Method
1Evidence-Based Medicine
1Ferritins (blood)
1Glucocorticoids (administration & dosage)
1Hospitals, Community
1Human
1Immunoglobulin Fab Fragments (therapeutic use)
1Immunosuppressive agent
1Infection
1Inflammatory joint disease
1Interest
1Interleukins (therapeutic use)
1International Cooperation
1Malignant tumor
1Medicine
1Meningitis (chemically induced)
1Meningitis (diagnostic imaging)
1Meningitis (physiopathology)
1Meningoencephalitis (chemically induced)
1Meningoencephalitis (diagnostic imaging)
1Meningoencephalitis (physiopathology)
1Metaanalysis
1Methotrexate (therapeutic use)
1Multiple
1Outcome Assessment, Health Care (methods)
1Outcome Assessment, Health Care (statistics & numerical data)
1Patient Education as Topic
1Phenotype
1Polyethylene Glycols (therapeutic use)
1Prednisone (administration & dosage)
1Prednisone (therapeutic use)
1Prognosis
1Randomized Controlled Trials as Topic
1Recurrence
1Remission Induction
1Retrospective Studies
1Risk Assessment
1Risk Factors
1Safety Management
1Sampling Studies
1Severity of Illness Index
1Spondylarthritis
1Still's Disease, Adult-Onset (blood)
1Toxicity
1Treatment strategy
1Tumor Necrosis Factor-alpha (therapeutic use)
1Young Adult

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Bruno Fautrel" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Bruno Fautrel" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Bruno Fautrel
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021